

**TOMAS OLSSON PUBLICATIONS 2016****Peer reviewed articles**

1. Abdelmagid N, Bereczky-Veress B, Atanur S, Musilova A, Zidek V, Saba L, Warnecke A, Khademi M, Studahl M, Aurelius E, Hjalmarsson A, Garcia-Diaz A, Denis CV, Bergstrom T, Skoldenberg B, Kockum I, Aitman T, Hubner N, Olsson T, Pravenec M, Diez M. Von Willebrand Factor Gene Variants Associate with Herpes simplex Encephalitis. *Plos One* 2016; 11.
2. Aeinehband S, Brenner P, Stahl S, Bhat M, Fidock MD, Khademi M, Olsson T, Engberg G, Jokinen J, Erhardt S, Piehl F. Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms. *Brain Behavior and Immunity* 2016; 51: 47-55.
3. Al Nimer F, Elliott C, Bergman J, Khademi M, Dring AM, Aeinehband S, Bergenheim T, Christensen JR, Sellebjerg F, Svenningsson A, Linington C, Olsson T, Piehl F. Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination. *Neurology-Neuroimmunology & Neuroinflammation* 2016; 3.
4. Alfredsson L, Hedstrom AK, Olsson T. Body mass index during adolescence, rather than childhood, is critical in determining multiple sclerosis risk. *Multiple Sclerosis Journal* 2016; 22: 193-193.
5. Alping P, Svenningsson A, Salzer J, Burman J, Dahle C, Fink K, Hillert J, Lycke J, Landtblom AM, Martin C, Nilsson P, Walentin F, Olsson T, Frisell T, Piehl F. Rituximab in multiple sclerosis; data from the swedish MS registry. *Multiple Sclerosis Journal* 2016; 22: 49-49.
6. Ayoglu B, Kockum I, Olsson T, Nilsson P. Anoctamin 2 identified as an autoimmune target in multiple sclerosis. *Multiple Sclerosis Journal* 2016; 22: 10-10.
7. Ayoglu B, Mitsios N, Kockum I, Khademi M, Zandian A, Sjoberg R, Forsstrom B, Bredenberg J, Bomfim IL, Holmgren E, Gronlund H, Guerreiro-Cacais AO, Abdelmagid N, Uhlen M, Waterboer T, Alfredsson L, Mulder J, Schwenk JM, Olsson T, Nilsson P. Anoctamin 2 identified as an autoimmune target in multiple sclerosis. *Proceedings of the National Academy of Sciences of the United States of America* 2016; 113: 2188-2193.
8. Barcellos LF, Gianfrancesco M, Shao X, Rhead B, Graves J, Waldman A, Lotze T, Schreiner T, Belman A, Greenberg B, Weinstock-Guttman B, Aaen G, Tillema JM, Hart J, Ness J, Harris Y, Rubin J, Candee M, Krupp L, Gorman M, Benson L, Rodrigue M, Chitnis T, Mar S, Kahn I, Rose J, Roalstad S, Casper TC, Shen L, Quach H, Metayer C, Glymour M, Walter S, Hubbard A, Jonsdottir I, Stefansson K, Strid P, Hillert J, Hedstrom A, Olsson T, Kockum I, Schaefer C, Waubant E, Alfredsson L. Body mass index is causally associated with pediatric and adult multiple sclerosis onset: a study of over 20,000 individuals using Mendelian Randomization. *Multiple Sclerosis Journal* 2016; 22: 192-193.

9. Bergman P, Piket E, Khademi M, James T, Brundin L, Olsson T, Piehl F, Jagodic M. Circulating miR-150 in CSF is a novel candidate biomarker for multiple sclerosis. *Neurology-Neuroimmunology & Neuroinflammation* 2016; 3.
10. Bistrom M, Gustafsson R, Engdahl E, Bomfim IL, Huang J, Jons D, Andersen O, Hortlund M, Alonso-Magdalenalena L, Waterboer T, Kockum I, Olsson T, Fogdell-Hahn A, Sundstrom P. Late Epstein-Barr virus infection and a second virus are linked to multiple sclerosis risk. *Multiple Sclerosis Journal* 2016; 22: 187-187.
11. Burkill S, Iacobaeus E, Bahmanyar S, Brundin L, Forede M, Olsson T, Montgomery S. Pharmacological Treatments Preceding Diagnosis Of Progressive Multifocal Leukoencephalopathy. *Pharmacoepidemiology and Drug Safety* 2016; 25: 496-497.
12. Engdahl E, Gustafsson R, Huang J, Bomfim IL, Khademi M, Michel A, Butt J, Brenner N, Hillert J, Alfredsson L, Waterboer T, Olsson T, Kockum I, Fogdell-Hahn A. Serological response against an immediately early protein 1 (IE1) protein sequence from HHV-6A, but not HHV-6B, is positively associated with multiple sclerosis. *Multiple Sclerosis Journal* 2016; 22: 859-860.
13. Forsberg L, Johansson S, Frisell T, Hillert J, Nilsson P, Dahle C, Sveningsson A, Lycke J, Landtblom AM, Burman J, Walentin F, Martin C, Piehl F, Olsson T. Real world experience of fingolimod after switching multiple sclerosis (MS) therapy; focus on natalizumab naive and experienced persons with MS, respectively. *Multiple Sclerosis Journal* 2016; 22: 647-648.
14. Forsberg L, Johansson S, Hillert J, Nilsson P, Dahle C, Sveningsson A, Lycke J, Landtblom AM, Burman J, Walentin F, Martin C, Piehl F, Olsson T. A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and effectiveness of dimethyl fumarate (IMSE 5). *Multiple Sclerosis Journal* 2016; 22: 338-339.
15. Frisell T, Forsberg L, Nordin N, Kiesel C, Alfredsson L, Askling J, Hillert J, Olsson T, Piehl F. Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis. *Multiple Sclerosis Journal* 2016; 22: 85-93.
16. Haggmark-Manberg A, Zandian A, Forsstrom B, Khademi M, Bomfim IL, Hellstrom C, Arnheim-Dahlstrom L, Hallbook T, Darin N, Lundberg IE, Uhlen M, Partinen M, Schwenk JM, Olsson T, Nilsson P. Autoantibody targets in vaccine-associated narcolepsy. *Autoimmunity* 2016; 49: 421-433.
17. Hedstroem AK, Olsson T, Alfredsson L. Smoking is a major preventable risk factor for multiple sclerosis. *Multiple Sclerosis Journal* 2016; 22: 1021-1026.
18. Hedstrom AK, Alfredsson L, Olsson T. Environmental factors and their interactions with risk genotypes in MS susceptibility. *Current Opinion in Neurology* 2016; 29: 293-298.
19. Hedstrom AK, Mowry EM, Gianfrancesco MA, Shao X, Schaefer CA, Shen L, Olsson T, Barcellos LF, Alfredsson L. High consumption of coffee is associated with decreased multiple sclerosis risk; results from two independent studies. *Journal of Neurology Neurosurgery and Psychiatry* 2016; 87: 454-460.

20. Hedstrom AK, Olsson T, Alfredsson L. Body mass index during adolescence, rather than childhood, is critical in determining MS risk. *Multiple Sclerosis Journal* 2016; 22: 878-883.
21. Hellberg S, Eklund D, Gawel DR, Kopsen M, Zhang H, Nestor CE, Kockum I, Olsson T, Skogh T, Kastbom A, Sjowall C, Vrethem M, Hakansson I, Benson M, Jenmalm MC, Gustafsson M, Ernerudh J. Dynamic Response Genes in CD4+T Cells Reveal a Network of Interactive Proteins that Classifies Disease Activity in Multiple Sclerosis. *Cell Reports* 2016; 16: 2928-2939.
22. Huang J, Bomfim IL, Michel A, Link J, Khademi M, Warnke C, Hillert J, Alfredsson L, Waterboer T, Olsson T, Kockum I. Genetic association of HLA alleles with JC polyomavirus and cross-reactivity with BK polyomavirus. *Multiple Sclerosis Journal* 2016; 22: 497-497.
23. Iacobaeus E, Burkill S, Bahmanyar S, Brundin L, Fored M, Olsson T, Montgomery S. Comorbid Diseases Preceding Diagnosis of Progressive Multifocal Leukoencephalopathy. *Pharmacoepidemiology and Drug Safety* 2016; 25: 99-99.
24. Johansson S, Forsberg L, Hillert J, Nilsson P, Dahle C, Svenningsson A, Lycke J, Landtblom AM, Burman J, Walentin F, Martin C, Piehl F, Olsson T. A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and effectiveness of natalizumab (IMSE 1). *Multiple Sclerosis Journal* 2016; 22: 336-337.
25. Kierkegaard M, Lundberg IE, Olsson T, Johansson S, Ygberg S, Opava C, Holmqvist LW, Piehl F. High-intensity resistance training in multiple sclerosis - An exploratory study of effects on immune markers in blood and cerebrospinal fluid, and on mood, fatigue, health-related quality of life, muscle strength, walking and cognition. *Journal of the Neurological Sciences* 2016; 362: 251-257.
26. Montgomery S, Hajiebrahimi M, Burkill S, Hillert J, Olsson T, Bahmanyar S. Multiple sclerosis and risk of young-adult-onset Hodgkin lymphoma. *Neurology-Neuroimmunology & Neuroinflammation* 2016; 3.
27. N'Diaye M, Warnecke A, Flytzani S, Abdelmagid N, Ruhrmann S, Olsson T, Jagodic M, Harris RA, Guerreiro-Cacais AO. Rat bone marrow-derived dendritic cells generated with GM-CSF/IL-4 or FLT3L exhibit distinct phenotypical and functional characteristics. *Journal of Leukocyte Biology* 2016; 99: 437-446.
28. Ockinger J, Hagemann-Jensen M, Kullberg S, Engvall B, Eklund A, Grunewald J, Piehl F, Olsson T, Wahlstrom J. T-cell activation and HLA-regulated response to smoking in the deep airways of patients with multiple sclerosis. *Clinical Immunology* 2016; 169: 114-120.
29. Ockinger J, Hagemann-Jensen M, Kullberg S, Engvall B, Eklund A, Grunewald J, Piehl F, Olsson T, Wahlstrom J. Investigation of patients with multiple sclerosis using bronchoalveolar lavage indicates T-cell activation in the lung and HLA-regulated response to smoke. *Scandinavian Journal of Immunology* 2016; 83: 369-369.
30. Olsson TM, Sundell K. Research that Guides Practice: Outcome Research in Swedish PhD Theses Across Seven Disciplines 1997-2012. *Prevention Science* 2016; 17: 525-532.

31. Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hemmer B, Hartung HP, Havrdova E, Kappos L, Liblau R, Lubetzki C, Miller DH, Olsson T, Selmaj C, Siva A, Sorensen PS, Thalheim C, Wiendl H, Zipp F, Thompson AJ, Gold R, Montalban X,ECTRIMS-EAN Ms Treatment G.ECTRIMS-EAN clinical practice guideline on pharmacological management of multiple sclerosis. *Multiple Sclerosis Journal* 2016; 22: 834-834.
32. Parsa R, Lund H, Tosevski I, Zhang XM, Malipiero U, Beckervordersandforth J, Merkler D, Prinz M, Gyllenberg A, James T, Warnecke A, Hillert J, Alfredsson L, Kockum I, Olsson T, Fontana A, Suter T, Harris RA. TGF beta Regulates Persistent Neuroinflammation by Controlling Th1 Polarization and ROS Production via Monocyte-Derived Dendritic Cells. *Glia* 2016; 64: 1925-1937.
33. Piehl F, Kockum I, Khademi M, Blennow K, Norgren N, Zetterberg H, Olsson T. High sensitivity measurement of neurofilament-light levels in plasma demonstrates a significant reduction in multiple sclerosis patients starting fingolimod. *Multiple Sclerosis Journal* 2016; 22: 672-672.
34. Rhead B, Baarnhielm M, Gianfrancesco M, Mok A, Shao X, Quach H, Shen L, Schaefer C, Link J, Gyllenberg A, Hedstrom AK, Olsson T, Hillert J, Kockum I, Glymour MM, Alfredsson L, Barcellos LF. Mendelian randomization provides evidence for a causal effect of low vitamin D on multiple sclerosis risk in two independent populations. *Multiple Sclerosis Journal* 2016; 22: 191-191.
35. Rosjo E, Lossius A, Abdelmagid N, Lindstrom JC, Kampman MT, Jorgensen L, Sundstrom P, Olsson T, Steffensen LH, Torkildsen O, Holmoy T. Selective and transient effect of vitamin D-3 supplementation on antibody responses against Epstein-Barr virus nuclear antigen 1 in relapsing-remitting multiple sclerosis. *Multiple Sclerosis Journal* 2016; 22: 500-500.
36. Sjostrand M, Johansson A, Aqrabi L, Olsson T, Wahren-Herlenius M, Espinosa A. The Expression of BAFF Is Controlled by IRF Transcription Factors. *Journal of Immunology* 2016; 196: 91-96.
37. Tengvall K, Bomfim IL, Michel A, Huang J, Ayoglu B, Alfredsson L, Nilsson P, Waterboer T, Olsson T, Kockum I. Anoctamin 2 as a multiple sclerosis autoantigen - replication of antibody reactivity in a larger cohort. *Multiple Sclerosis Journal* 2016; 22: 746-746.